Non-responders are those children who have shown minimal efficacy of their treatment in myopia control studies, and it turns out that there’s around 15-20% of children who are classified this way across the major myopia control intervention studies. We look at non-responders in atropine, multifocal and myopia controlling contact lens, orthokeratology and DIMS spectacle lens studies, and what factors non-responders share across these studies.
When myopia progression seems to be faster than expected for a myopia control treatment, various factors can be at play, such as non-compliance, user error, high myopia, binocular vision, visual environment. Or you may have a non-responder on your hands. What should you do? Read more here.
This review covers how well axial length relates to refraction and predicting future myopia, how to measure axial length, its value in orthokeratology and atropine management, how axial length influences a treatment plan and can you practice myopia management without it.
Myopia has multi-factorial causes with both nature and nurture contributing. In this research the authors used a retrospective cohort study to examine any differences in progression rate with different ethnicities and greater understand who may be at increased risk of myopic progression.
Low dose atropine is often used for myopia control in children. How commonly will patients complain of side effects, such as photophobia, allergy or blurry vision at near? BL presents a patient who experienced blurry vision after using 0.01% atropine once, and subsequently refused to use it. This led to significant fear and misconception on the part of the parent. How should a case like this be managed?
You may be ready to cease treatment, or the patient has done so of their own accord. Then you observe that the rate of myopic progression accelerates again – a myopia rebound effect. When does this happen? Can you avoid it? What should you consider doing in practice?
Professor Karla Zadnik, Dean of the Ohio State University College of Optometry in the USA,, discusses the Childhood Atropine for Myopia Progression (CHAMP) study, engaging with the literature, her favourite papers and an alternative take on myopia control as standard of care.
The research information on using atropine for myopia control is evolving. Previous research indicated 0.01% atropine was best, but newer research says otherwise. In this clinical case, practitioners discuss treatment strategies, which are put in research context with clinical pearls for practice.
A child has an allergic reaction to low dose atropine – or does he? Here practitioners consider the possible causes, with advice for management. We then frame this discussion in view of the evidence-base with take home clinical messages.
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
